Discovery research is an ever more difficult investment to justify, so companies are placing greater emphasis on mining discoveries that have already been made but whose real value remains unexploited. Big Pharma, in part inhibited by habit and current infrastructure, has not moved aggressively in the new direction-but the jumpstart model now dominates small-company strategies and will increasingly translate into the rest of the industry.
By Roger Longman
Business development is now as important to most drug companies as internal discovery—literally. For the top 15 drug companies, according...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
